Response to Lehrer and Rheinstein

Karen M Tuesley^{1

2}, Penelope M Webb^{1

2}, Melinda M Protani¹, Katrina Spilsbury³, Sallie-Anne Pearson⁴, Michael D Coory⁵, Peter Donovan^{6

7}, Christopher Steer^{8

9}, Louise M Stewart¹⁰, Nirmala Pandeya^{1

2}, Susan J Jordan^{1

2}

Affiliations

¹ School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia.
² Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
³ Institute for Health Research, The University of Notre Dame Australia, Fremantle, Australia.
⁴ Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
⁵ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
⁶ Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
⁷ Faculty of Medicine, University of Queensland, Brisbane, Australia.
⁸ Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, Albury, Australia.
⁹ University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.
¹⁰ School of Population and Global Health, The University of Western Australia, Perth, Australia.

Comment

Karen M Tuesley et al. J Natl Cancer Inst. 2022.

. 2022 Oct 6;114(10):1427-1428.

doi: 10.1093/jnci/djac083.

¹ School of Public Health, Faculty of Medicine, University of Queensland, Brisbane, Australia.
² Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
³ Institute for Health Research, The University of Notre Dame Australia, Fremantle, Australia.
⁴ Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.
⁵ Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
⁶ Clinical Pharmacology Department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
⁷ Faculty of Medicine, University of Queensland, Brisbane, Australia.
⁸ Border Medical Oncology, Albury-Wodonga Regional Cancer Centre, Albury, Australia.
⁹ University of NSW Rural Clinical School, Albury Campus, Albury, New South Wales, Australia.
¹⁰ School of Population and Global Health, The University of Western Australia, Perth, Australia.

No abstract available

Comment in

RE: Nitrogen-Based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
Lehrer S, Rheinstein PH. Lehrer S, et al. J Natl Cancer Inst. 2022 Oct 6;114(10):1425-1426. doi: 10.1093/jnci/djac082. J Natl Cancer Inst. 2022. PMID: 35460254 Free PMC article. No abstract available.

Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older.
Tuesley KM, Webb PM, Protani MM, Spilsbury K, Pearson SA, Coory MD, Donovan P, Steer C, Stewart LM, Pandeya N, Jordan SJ. Tuesley KM, et al. J Natl Cancer Inst. 2022 Jun 13;114(6):878-884. doi: 10.1093/jnci/djac050. J Natl Cancer Inst. 2022. PMID: 35262727 Free PMC article.

1. Lehrer S, Rheinstein PH. RE: Nitrogen-based bisphosphonate use and ovarian cancer risk in women aged 50 years and older. J Natl Cancer Inst. 2022. doi: 10.1093/jnci/djac082. - DOI - PMC - PubMed
1. Zhang XS, Zhang YM, Li B, Fan B, Zhao Y, Yang SJ. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: a meta-analysis. Gynecol Oncol. 2018;150(3):509–514. - PubMed
1. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases. Br J Cancer. 2013;109(3):795–806. - PMC - PubMed
1. Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. JCO. 2016;34(24):2888–2898. doi:10.1200/JCO.2016.66.8178. - DOI - PMC - PubMed
1. Gnjidic D, Du W, Pearson SA, Hilmer SN, Banks E. Ascertainment of self-reported prescription medication use compared with pharmaceutical claims data. Public Health Res Pract. 2017;27(4):27341702. doi:10.17061/phrp27341702. - DOI - PubMed